SLN - Silence Therapeutics PLC

SLN - Silence Therapeutics PLC

https://www.silence-therapeutics.com

Recent News

Powered by Alpha Vantage

Silence Therapeutics ( SLN ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 6 months, 1 week ago • score: 0.38

Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - AZZ ( NYSE:AZZ ) , Gaia ( NASDAQ:GAIA )

Benzinga • 7 months ago • score: 0.16

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Top 3 Health Care Stocks That May Explode In Q4 - ModivCare ( NASDAQ:MODV ) , Olema Pharmaceuticals ( NASDAQ:OLMA )

Benzinga • 8 months, 4 weeks ago • score: -0.24

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Zacks Commentary • 9 months, 3 weeks ago • score: -0.01

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst - Silence Therapeutics ( NASDAQ:SLN )

Benzinga • 9 months, 3 weeks ago

On Monday, Silence Therapeutics plc SLN presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease ( ASCVD ) patients with high lipoprotein ( a ) [Lp ( a ) ] levels ( ≥125 nmol/L ) .

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.

52W High

$20.48

52W Low

$1.97

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.38

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.78

EV/Revenue (<3 favorable)

3.32

P/S (TTM) (<3 favorable)

9.89

P/B (<3 favorable)

2.85

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

24.38%

Institutions (25–75% balanced)

44.31%

Shares Outstanding

47,233,900

Float

74,748,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

27,169,000

Gross Profit (TTM)

21,353,000

EPS (TTM)

-1.68

Profit Margin (>10% good)

-2.91%

Operating Margin (TTM) (higher better)

-90.48%

ROE (TTM) (>15% strong)

-0.67%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.70

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—